

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/288289 A3

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/712 (2006.01)
A61K 31/7125 (2006.01) G16B 30/00 (2019.01)

(21) International Application Number:

PCT/US2022/073754

(22) International Filing Date:

14 July 2022 (14.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/221,568 14 July 2021 (14.07.2021) US

(71) Applicant: **MIRECULE, INC.**, [US/US]; 704 Quince Orchard Road, Suite 140, Gaithersburg, MD 20878 (US).

(72) Inventors: **SALEH, Anthony**; c/o miRecule, Inc., 704 Quince Orchard Road, Suite 140, Gaithersburg, MD 20878 (US). **BELGARD, Grant**; 7376 Bella Foresta Place, Sanford, FL 32771 (US). **MUNZ, Marton**; c/ Ventallóg 75, P02

PTA1, Barcelona, Barcelona (ES). **MARUSAK, Charles**; c/o miRecule, Inc., 704 Quince Orchard Road, Gaithersburg, MD 20878 (US). **PLACE, Robert**; c/o miRecule, Inc., 704 Quince Orchard Road, Suite 140, Gaithersburg, MD 20878 (US).

(74) Agent: **VELEMA, James, H.** et al.; Lathrop GPM LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: OLIGONUCLEOTIDES AND COMPOSITIONS THEREOF FOR NEUROMUSCULAR DISORDERS




FIG. 1

(57) Abstract: Disclosed herein are engineered DUX4-targeting oligonucleotides for selective inhibition of RNA transcripts associated with a neuromuscular disease such as facioscapulohumeral muscular dystrophy. Also disclosed are vectors containing any of these, pharmaceutical formulations containing any of the these, and kits containing any of the these. Also disclosed herein are methods of selectively inhibiting polypeptide expression and activity by contacting a DUX4-targeting oligonucleotide with an RNA transcript associated with a neuromuscular disease such as facioscapulohumeral muscular dystrophy.

[Continued on next page]



WO 2023/288289 A3

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

13 April 2023 (13.04.2023)